Delta 9 Develops Proprietary Decontamination Technology to Help Fight COVID-19 Pandemic


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Delta 9 Develops Proprietary Decontamination Technology to Help Fight COVID-19 Pandemic
DELTA 9 CANNABIS INC is pleased to announce that it has developed and validated new proprietary decontamination Technology, which helps to fight COVID-19 Pandemic.

DELTA 9 CANNABIS INC is pleased to announce that it has developed and validated new proprietary decontamination equipment, branded the “Decontamination Pod” (or “D-Pod”), which can be used to decontaminate medical supplies, personal protective equipment (“PPE”), and other equipment.

Canadian and US patent applications have been filed on behalf of the Company for the D-Pod, which is a standard shipping container retrofitted to include heating and ultraviolet light technologies. When PPE or other materials are placed inside the treatment area of the D-Pod, the combination of heat and UVC is sufficient to kill the COVID-19 virus.

“This technology could be a game-changer for governments, hospitals, and care facilities in the fight against COVID-19, allowing them to decontaminate large amounts of PPE and other equipment, increasing the availability of existing PPE inventories and preventing potential exposures to the virus,” said John Arbuthnot, CEO of Delta 9. “We are extremely proud of our employees and partners for bringing this technology to this point and look forward to continuing to do our part in providing solutions to this health crisis.”

The Company, through a newly incorporated and partially owned subsidiary, Blue Horseshoe Manufacturing Inc., plans to manufacture and distribute the new technology across North America, providing a new tool for governments, health care facilities, long-term care facilities, businesses, and First Nations in their fight against COVID-19.

The Company will leverage the success of its cannabis grow pod division which has produced and installed over 500 pods for in-house and third-party facilities since 2017 and use its existing cannabis grow pod manufacturing facilities in Winnipeg to manufacture the first D-Pods.

Management believes that the Company will quickly be able to ramp up production capacity to 16 to 20 D-Pods per month while working with other Canadian manufacturers to compliment its internal capacity. The D-Pods are expected to sell for approximately $250,000 per unit. The Company has already received inquiries from groups interested in deploying the technology and expects to begin taking orders in the coming week.

The technology used in the D-Pods was originally developed in partnership between Delta 9, RSR Project Management Ltd., Northern Green Homes Inc., and Connco Electric and the finished D-Pod was tested and validated by an independent and accredited third party lab, BioScision Pharma Inc., which confirmed that the technology should be effective in decontaminating materials which may be contaminated with the COVID-19 virus.

The D-Pod is the first innovation of Delta 9’s grows pod business unit which can be used as a tool in the fight against COVID-19. The Company is now developing additional technologies that can decontaminate equipment at low temperatures and modular storage and transport units that can be used to store and distribute vaccines while maintaining quality and stability.

Tags : #Delta9Cannabis #DecontaminationPod #DecontaminationTechnology #FightAgainstCovid19 #Covid19 #BlueHorseshoe #D-Pod #CoronaVirus

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026